Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Post-Birth sugar check reveals hidden diabetes risk in moms

NCT ID NCT01839448

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 500 women who had gestational diabetes during pregnancy. They took a glucose test 4 to 12 weeks after giving birth to see how many had type 2 diabetes, impaired glucose tolerance, or impaired fasting glucose. The goal was to compare women diagnosed with gestational diabetes before 24 weeks of pregnancy versus those diagnosed after 24 weeks. The study does not test a treatment but aims to improve understanding of postpartum diabetes risk.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors better understand when to screen for diabetes after pregnancy, leading to earlier detection and prevention of type 2 diabetes.
What could go wrong
This is an observational study, not a treatment trial. It only measures outcomes without testing any intervention, so it cannot directly improve health. Results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

500 people

The number who actually took part.

Started

Mar 2014

Finished

Oct 2016

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population is composed of pregnant women consulting before 24 weeks of amenorrhea and who have at least one of the following risk factors: age \> 35 years; body mass index \> 25; a family history of type 2 diabetes; a history of gestational diabetes or macrosomia.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The patient must have given her informed and signed consent * The patient must be insured or beneficiary of a health insurance plan * The patient is available for 10 months of follow-up * The patient is pregnant and consulting before 24 weeks of amenorrhea AND has at least one of the following risk factors: age \> 35 years; body mass index \> 25; family history of type 2 diabetes; history of gestational diabetes; history of macrosomia. * The patient has a fasting blood glucose level \>= 0.92 g/l before 24 weeks of amenorrhea OR a fasting blood glucose level \< 0.92 g/l before 24 weeks of amenorrhea AND an abnormal oral glucose tolerance test (75 g of glucose) between 24 and 28 weeks of amenorrhea (normal values are set at T0 \< 0.92 g/l; T60 \< 1.80 g/l; T120 \< 1.53 g/l). Exclusion Criteria: * The patient is participating in another study * The patient is in an exclusion period determined by a previous study, with the exception of the following studies: Papillo PMA (RCB 2013-A00538-37), LXRs (RCB 2009-A00968-49), GrossPath (RCB 2014-A01120-47), BAKRI (RCB 2013-A00914-41), OASIS II (RCB 2013-A00773-42), ElastoMAP (RCB 2013-A01148-37), ElastoDéclench (RCB 2014-A00828-39) and UpSideDown (RCB 2014-A01921-46). * The patient is under judicial protection, under tutorship or curatorship * The patient refuses to sign the consent * It is impossible to correctly inform the patient * The patient cannot read French * The patient has a known history of type 2 diabetes * The patient is diagnosed with type 2 diabetes during pregnancy (fasting blood glucose level \> 1.26 g/l) * The patient has a contra-indication for a treatment necessary for this study * The patient is taking chronic or intermittent oral or inhaled corticosteroids, or a β2 agonist treatment for a previous disease or a disease discovered during pregnancy within one week preceding the fasting glucose or oral glucose tolerance test.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gestational diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CH d'Arles - Hôpital Joseph Imbert

    Arles, 13637, France

  • CHU de Montpellier - Hôpital Arnaud de Villeneuve

    Montpellier, 34295, France

  • CHU de Montpellier - Hôpital Lapeyronie

    Montpellier, 34295, France

  • CHU de Nîmes - Hôpital Universitaire Carémeau

    Nîmes, 30029, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.